PTPRC and congestive heart failure: Regarding PS−-EVs, significantly reduced levels of CD3+/AV−-EVs (lEVs; p = 0.003), CD45+/AV−-EVs (LEVs; p = 0.0036), CD15+/AV−-EVs (nEVs; p < 0.001), and CD56+/AV−-EVs (NKc-EVs; p = 0.005) were found in the non-HF control subjects compared to the cHF patients (Figure S1).